https://charts.traderzeitung.de/phases/US3968791083 string(1463) "{"isin":"US3968791083","name":"Greenwich LifeSciences Inc","stock_id_xnas":15155035,"stock_id_xnys":null,"generated_at":"2026-09-21 09:36:00","days":[{"date":"2026-09-16","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":15.75,"close_at":"2026-09-16 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-17","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":15.73,"close_at":"2026-09-17 15:27:00","complete":true,"perf_pct":-0.127},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":18.435,"close_at":"2026-09-17 21:59:00","complete":true,"perf_pct":17.1964},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":18.43,"close_at":"2026-09-18 00:45:00","complete":true,"perf_pct":-0.0271}]},{"date":"2026-09-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":18.91,"close_at":"2026-09-18 21:59:00","complete":true,"perf_pct":2.6044},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":19,"close_at":"2026-09-18 22:59:00","complete":true,"perf_pct":0.4759}]}]}"

Greenwich LifeSciences Aktie News & Nachrichten

[WKN: A2P794 | Symbol: GLSI]

Realtimekurs

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

15.01.2026 um 15 Uhr

Greenwich LifeSciences

Greenwich Lifesciences: Vorstand erhöht seine Beteiligung auf 5,6 Mio. Aktien!

Greenwich Lifesciences (GLSI) ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich...

Greenwich LifeSciences Nachrichtenticker öffnen

MT Newswires 22.07.2026 13:50 Uhr

Greenwich LifeSciences Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Greenwich Lifesciences: Vorstand erhöht seine Beteiligung auf 5,6 Mio. Aktien!

Greenwich LifeSciences erhält britische Genehmigung zur Ausweitung der Brustkrebsstudie

Greenwich LifeSciences: EU-Regulierungsbehörde genehmigt Einbeziehung von HLA-Patienten beider Typen in Phase-3-Studie

Sektor-Update: Gesundheitsaktien vorbörslich uneinheitlich am Donnerstag

Sektor-Update: Gesundheitswesen

Greenwich LifeSciences sagt, kommerziell hergestelltes GP2 für Studien in Europa freigegeben

Greenwich LifeSciences sagt, Prüfung der 2025er Form 10-K-Einreichung in der Endphase der Genehmigung